Nektar Therapeutics reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 24.92 million compared to USD 30.03 million a year ago. Net loss was USD 129.71 million compared to USD 108.59 million a year ago. Basic loss per share from continuing operations was USD 0.7 compared to USD 0.61 a year ago. For the nine months, revenue was USD 76.9 million compared to USD 129.45 million a year ago. Net loss was USD 378.19 million compared to USD 327.24 million a year ago. Basic loss per share from continuing operations was USD 2.07 compared to USD 1.84 a year ago.